[go: up one dir, main page]

SG11201607137WA - Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain - Google Patents

Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain

Info

Publication number
SG11201607137WA
SG11201607137WA SG11201607137WA SG11201607137WA SG11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA
Authority
SG
Singapore
Prior art keywords
prevention
compositions
treatment
methods
weight gain
Prior art date
Application number
SG11201607137WA
Inventor
Arun K Tiwari
Eva J Brandl
Nabilah I Chowdhury
Vanessa F Gonçalves
Jennie G Pouget
James L Kennedy
Daniel J Mueller
Clement C Zai
Original Assignee
Camh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camh filed Critical Camh
Publication of SG11201607137WA publication Critical patent/SG11201607137WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
SG11201607137WA 2014-02-28 2015-02-27 Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain SG11201607137WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461946003P 2014-02-28 2014-02-28
US201462056250P 2014-09-26 2014-09-26
US201462059358P 2014-10-03 2014-10-03
PCT/CA2015/050145 WO2015127557A1 (en) 2014-02-28 2015-02-27 Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain

Publications (1)

Publication Number Publication Date
SG11201607137WA true SG11201607137WA (en) 2016-09-29

Family

ID=54008095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607137WA SG11201607137WA (en) 2014-02-28 2015-02-27 Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain

Country Status (10)

Country Link
US (1) US10662475B2 (en)
EP (1) EP3111352A4 (en)
JP (1) JP6588919B2 (en)
KR (1) KR20160138071A (en)
CN (1) CN106462668A (en)
AU (1) AU2015222658B2 (en)
CA (1) CA2940908C (en)
IL (1) IL247410B (en)
SG (1) SG11201607137WA (en)
WO (1) WO2015127557A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
US20190046532A1 (en) * 2015-09-30 2019-02-14 Indivior Uk Limited Psychiatric treatment for patients with gene polymorphisms
CN105467028A (en) * 2015-11-18 2016-04-06 北京万全德众医药生物技术有限公司 A method of separating and measuring optical isomers of a lurasidone intermediate by gas chromatography
AU2017218149B2 (en) 2016-02-12 2020-09-03 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110087640A (en) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
CN109207582A (en) * 2018-10-22 2019-01-15 南通中科基因医学检验所有限公司 Clozapine Personalized Medicine Genetic Testing Kit
CN118841129B (en) * 2024-09-23 2024-12-13 深圳人体密码基因科技有限公司 Gene detection report generation method and system based on medication risk assessment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
PT728218E (en) 1993-11-12 2008-04-08 Phri Properties Inc Hybridization probes for nucleic acid detection, universal stems, methods and kits
AU2002363329A1 (en) * 2001-11-06 2003-05-19 Elizabeth Gray Pharmacogenomics-based system for clinical applications
US20060177847A1 (en) * 2004-12-09 2006-08-10 Perlegen Sciences, Inc. Markers for metabolic syndrome obesity and insulin resistance

Also Published As

Publication number Publication date
AU2015222658A1 (en) 2016-09-08
US20170073755A1 (en) 2017-03-16
EP3111352A4 (en) 2017-08-30
KR20160138071A (en) 2016-12-02
JP2017506518A (en) 2017-03-09
EP3111352A1 (en) 2017-01-04
WO2015127557A1 (en) 2015-09-03
US10662475B2 (en) 2020-05-26
JP6588919B2 (en) 2019-10-09
CN106462668A (en) 2017-02-22
CA2940908A1 (en) 2015-09-03
IL247410A0 (en) 2016-11-30
IL247410B (en) 2020-05-31
AU2015222658B2 (en) 2021-07-08
CA2940908C (en) 2023-05-09

Similar Documents

Publication Publication Date Title
IL277069B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
ZA201705908B (en) Compositions and methods for the reduction or prevention of hepatic steatosis
IL247410A0 (en) Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
IL247515A0 (en) Cenicriviroc for the treatment of fibrosis
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
HUE056172T2 (en) Compositions of selenoorganic compounds and methods of use thereof
PL3102555T3 (en) Compositions of compounds and uses thereof
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
IL246721B (en) Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases
EP3113788A4 (en) Methods and compositions for the protection of sensory cells
PT3122349T (en) Compositions for the treatment of autodigestion
IL253220A0 (en) Compositions and methods for treating glaucoma
PL3113774T3 (en) Compositions of grapiprant and methods for using the same
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
IL248846A0 (en) Methods and compositions of dasotraline for treatment of adhd
EP3104940A4 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
AU2014904752A0 (en) Methods for the treatment and prevention of iron overload
GB201418272D0 (en) Composition & methods of treatment
GB201418268D0 (en) Composition & methods of treatment
HK1231001A1 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis